Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09989 Shenzhen Hepalink Pharmaceutical Group Co Ltd HKSE:09989
85 GF Score
Price HK$3.88
GF Value HK$4.73
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Shenzhen Hepalink Pharmaceutical Group Co  (HKSE:09989) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio Related Terms


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.18 1.35 0.86 0.94 1.22

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.27 1.30 1.22 1.14 0.95

HKSE:09989 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio falls into.


HKSE:09989
85GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd HKSE:09989
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Shenzhen Hepalink Pharmaceutical Group Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.98/116.0564*116.0564
=0.980

Current CPI (Jun. 2026) = 116.0564.

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.715 99.500 0.834
201509 0.627 100.500 0.724
201512 1.017 100.600 1.173
201603 0.997 102.200 1.132
201606 0.494 101.400 0.565
201609 0.423 102.400 0.479
201612 0.563 102.600 0.637
201703 0.412 103.200 0.463
201706 0.541 103.100 0.609
201709 0.668 104.100 0.745
201712 0.920 104.500 1.022
201803 0.943 105.300 1.039
201806 1.216 104.900 1.345
201809 1.031 106.600 1.122
201812 1.341 106.500 1.461
201909 0.904 109.800 0.956
201912 1.323 111.200 1.381
202009 0.674 111.700 0.700
202012 1.427 111.500 1.485
202103 1.035 112.662 1.066
202106 1.512 111.769 1.570
202109 1.244 112.215 1.287
202112 1.440 113.108 1.478
202203 1.601 114.335 1.625
202209 1.278 115.339 1.286
202212 1.322 115.116 1.333
202303 1.016 115.116 1.024
202306 1.075 114.558 1.089
202309 0.994 115.339 1.000
202312 1.018 114.781 1.029
202403 1.018 115.227 1.025
202406 1.075 114.781 1.087
202409 0.913 115.785 0.915
202412 0.893 114.893 0.902
202503 1.016 115.116 1.024
202506 1.046 114.907 1.056
202509 1.026 115.471 1.031
202512 0.960 115.832 0.962
202603 1.023 116.303 1.021
202606 0.980 116.056 0.980

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of HK$3.88 is trading 18% below its estimated GF Value™ of HK$4.73. GuruFocus considers Shenzhen Hepalink Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for HKSE:09989:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: HK$4.73 vs. price of HK$3.88 (18% below fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the HKSE:09989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
85GF Score

Get the complete analysis for HKSE:09989

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.88
Price
HK$4.73
GF Value